A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

NCT04282031 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
HR+/HER2- Breast Cancer

Interventions

DRUG: BPI-1178
DRUG: Fulvestrant
DRUG: Letrozole
DRUG: BPI-1178

Sponsor

Beta Pharma (Suzhou) Co., Ltd.